Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
Additional studies are needed to further evaluate PH-762’s safety and efficacy.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Phio Pharmaceuticals (PHIO) will present final Phase 1b clinical results for PH-762 at the SITC meeting on November 7, 2026. Lead investigator John Strasswimmer will deliver the oral presentation in Phoenix, Arizona.
The study assessed PH-762 injected directly into tumors before surgery for cutaneous carcinomas. Phio said findings suggest the treatment is well-tolerated and may offer a tissue-sparing option before surgery for cutaneous squamous cell carcinoma. A Phase 2b study is planned for the first half of 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Phio plans a Phase 2b study in the first half of 2027.
- Minor pointPhase 1b findings suggest PH-762 is well-tolerated and may offer a tissue-sparing treatment before surgery.
Negative
- None.
Key Figures
- Trial phase
- Phase 1b
- Final results of the first PH-762 study
- Phase 2b study timing
- First half of 2027
- Planned follow-up study
Historical Context
-
First commercial-scale PH-762 drug-substance batch released for the planned Phase 2b study.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
sirna medical
neoadjuvant medical
intratumoral injection medical
cscc medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell Carcinoma
King of Prussia, Pennsylvania--(Newsfile Corp. - November 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it will present clinical data from its Phase 1b clinical trial at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in Phoenix, Arizona from November 6-8, 2026.
"The growing body of clinical evidence suggests that PH-762 may offer patients and physicians a meaningful new treatment option capable of shrinking tumors prior to surgery while maintaining an attractive safety profile," said Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals. "We believe these findings support PH-762's potential to become a differentiated, tissue-sparing neoadjuvant treatment that may reduce the burden of surgery while preserving favorable clinical outcomes."
Phio's presentation will be made by John Strasswimmer, M.D., Ph.D., Florida Atlantic University, Delray Beach, FL; Integrity Research at Dermatology Assoc. of the Palm Beaches, Inc., Delray Beach, FL and lead investigator for the Phase 1b clinical trial. Highlights of the presentation include final results of the first Phase 1b study assessing the safety and efficacy of INTASYL PH-762 as a neoadjuvant intratumoral injection for cutaneous carcinomas. Study findings suggest PH-762 is well-tolerated and may represent a tissue-sparing neoadjuvant to the current cSCC treatment standard of MMS and/or standard excision. Additional studies are needed to further evaluate the safety and efficacy of PH-762 and a Phase 2b study is planned for the first half of 2027.
Presentation Details are as follows:
| Title of the Presentation: | Neoadjuvant Phase 1b Results: Dose Escalation of Intratumoral PH-762 for Cutaneous SCC, Melanoma, or Merkel Cell (NCT 06014086) |
| Presenter: | John Strasswimmer, M.D., Ph.D. |
| Presentation Date/Time: | Saturday, November 7; 2:45 PM - 3:00 PM |
| Location/Venue: | Phoenix Convention Center, Halls BC |
| Session Name: | Clinical Oral Abstract Session 2 |
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements, among other things, regarding the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells, the potential for PH-762 to offer patients and physicians a meaningful new treatment option capable of shrinking tumors prior to surgery while maintaining an attractive safety profile, the potential for PH-762 to become a differentiated, tissue-sparing neoadjuvant treatment that may reduce the burden of surgery while preserving favorable clinical outcomes, and our expectation that a Phase 2b study will occur in the first half of 2027, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact of future FDA interactions on the development of our product candidates; the impact to our business and operations by inflationary pressures; recession fears; the development of our product candidates, results from our nonclinical, preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the U.S. Securities and Exchange Commission. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/322719
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will Phio present its PH-762 Phase 1b results at SITC?
Phio’s oral presentation is scheduled for November 7, 2026, from 2:45 PM to 3:00 PM. Lead investigator John Strasswimmer will present during Clinical Oral Abstract Session 2 at the Phoenix Convention Center, Halls BC.
What did Phio report about PH-762’s Phase 1b findings?
Phio said the findings suggest PH-762 is well-tolerated and may offer a tissue-sparing treatment before surgery for cutaneous squamous cell carcinoma. The study assessed safety and efficacy using injections directly into tumors. Additional studies are needed to further evaluate safety and efficacy.